Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bacterial WGS validation panel

ABSTRACT: Bacterial WGS validation panel

PROVIDER: PRJNA341407 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR4114370_1.fastq.gz	Fastqsanger.gz
	SRR4114370_2.fastq.gz	Fastqsanger.gz
	SRR4114380_1.fastq.gz	Fastqsanger.gz
	SRR4114380_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 343

Similar Datasets

Bovine-TB WGS Validation

Project description:Bovine-TB WGS Validation

| PRJEB40440 | ENA

Diagnostic Accuracy of a Panel of Bacterial Gene Markers (M3) for Colorectal Advanced Neoplasia

Project description:The investigators aim to evaluate and compare the diagnostic accuracy of FIT and the novel panel of bacterial gene markers (Fn, m3, Ch and Bc) collectively named as M3, in detecting colorectal advanced neoplasia.

| 2733246 | ecrin-mdr-crc

TB WGS

Project description:TB WGS validation

| PRJEB25543 | ENA

ISS bacterial species WGS

Project description:WGS bacterial species isolated from the International Space Station. Genome sequencing and assembly

| PRJNA641401 | ENA

WGS analysys of mcr positive bacterial isolates

Project description:WGS analysys of mcr positive bacterial isolates

| PRJEB43940 | ENA

A comprehensive assessment of a newly designed non-exonic SNP-based NGS panel for HRD detection

Project description:Ovarian cancer is a global problem, is typically diagnosed at a late stage and has no effective screening strategy. Platinum-based chemotherapy or Poly(ADP-ribose) polymerase inhibitors (PARPis) treatment are most frequently applied for ovarian cancer patients who are inoperable and in the advanced stage. The recognition of homologous recombination deficiency (HRD) as a biomarker to predict the effect of Platinum-based or PARPis treatment. WGS and WES can detect tumor HRD status but have several disadvantages which restrict their clinical application. My choice HRD CDx and Foundation Focus CDx are approved by FDA for HRD detection, however, whether they are applicable to the Chinese population or not is unknown. In this study, we created an SNP-based Tg-NGS panel to fill in gaps in Chinese patients’ HRD screening. Our results showed that the panel is cost and time-saving compared with WGS, but equivalent with SNP microarray on CNV and HRD detection. In summary, this newly developed kit is promising in clinical application to guide ovarian cancer and even other cancer types therapy.

2023-02-21 | GSE203509 | GEO

Discovery and validation of serum glycoprotein biomarker panel for detection of high grade serous ovarian cancer

Project description:We aimed to discover and validate a panel of serum biomarkers for high grade serous ovarian cancer (HGSOC) using our lectin-magnetic bead array-coupled proteomics platform. Serum from age-matched women with HGSOC, benign tumours or healthy controls were analysed in discovery (UKCTOCS, n=30 and UKOPS, n=30) and validation (Australian Ovarian Cancer Study, n=95) cohorts using shotgun and targeted proteomics, respectively. A 7-lectin discovery screen shortlisted 60 candidate proteins and 3 lectins for validation, which revealed elevated levels of AAL, SNA or STL-binding FIBB, CO9, ITIH3, HPT, A1AT, AACT in HGSOC, while IBP3, A2MG, PON1, CHLE and ALS were reduced. Multimarker panels were developed using generalized regression with lasso estimation and leave-one-out cross-validation. The best performing panel comprised of 13 peptides from Solanum Tuberosum lectin (STL)-binding proteins with 96.3% area under the receiver operating curve, 97.7% specificity and 78.6% sensitivity for distinguishing HGSOC from benign and healthy groups. The peptides robust in cross-validations were from IBP3, KNG1, CO9, THRB, HPTR, HPT, FINC, FA10, GELS. The validated serum biomarkers show promise for early detection of HGSOC and should be further evaluated.

2023-10-24 | PXD032299 | Pride

Identification and validation of a salivary protein panel to detect heart failure early

Project description:Background: Over 26 million people suffer from heart failure (HF) globally. Current diagnosis of HF relies on clinical evaluation, blood assays and imaging techniques at the time of diagnosis. Our aim is to develop a diagnostic assay to detect HF early in at risk individuals within the community using human saliva as a medium, paving the way towards precision medicine. Methods: Saliva samples were collected from healthy controls (n=36) and HF patients (n=75). Salivary proteome profiles were analysed by Sequential Window Acquisition of All Theoretical fragment ion spectra – Mass Spectrometry (SWATH-MS). A total of 738 proteins were quantified and 177 proteins demonstrated significant differences in saliva from HF patients and healthy controls. Candidate biomarkers were chosen based on their abundance and difference between the two cohorts. A multi-protein panel was developed using logistic regression analysis. The diagnostic performance of the multi-protein panel was assessed using the receiver operative characteristic curves. The candidate proteins were further validated technically, using western blot analysis as well as biologically, using an independent cohor.t. Results: A group of six proteins were chosen as potential protein candidates based on their differences in the abundance between the two cohorts. During the validation phase, two of the proteins were eliminated as these did not meet our criteria. The panel consists of four proteins with sensitivity of 83.3%, specificity of 62.5% with an area under ROC curve of 0.78 in discriminating healthy controls from NYHA class I/II HF patients. Conclusion: Analysis of salivary proteome using SWATH-MS analysis revealed novel HF-specific protein candidates when combined into a panel yielding high diagnostic performance. A multi-centre longitudinal clinical trial will be the next step before clinical implementation of this panel.

2018-10-24 | PXD007134 | Pride

DNA-seq (low-coverage WGS) for validation of CRISPR-Cas9-edited mESCs

Project description:DNA-seq (low-coverage WGS) for validation of CRISPR-Cas9-edited mESCs

| PRJEB61022 | ENA

WGS from HepG2 (ENCSR319QHO)

Project description:The data contained in this Experiment come from 10X Chromium Genomics WGS of HepG2 cell line For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2021-06-15 | GSE177129 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data